Tag : DEPEMOKIMAB

CONFERENCE UPDATE

Twice-yearly depemokimab sustains 2-year response in uncontrolled asthma: SWIFT/AGILE responder analysis
A post hoc responder analysis of the integrated SWIFT/AGILE studies demonstrated that twice-yearly depemokimab maintained clinically meaningful responses over 2 years in patients with uncontrolled asthma symptoms at baseline. Responses were sustained across exacerbations, St. George’s Respiratory Questionnaire (SGRQ) and Asthma Control Questionnaire-5 (ACQ-5), with greater increase following the switch from placebo to depemokimab.